BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1504 related articles for article (PubMed ID: 26901407)

  • 1. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.
    Gros A; Parkhurst MR; Tran E; Pasetto A; Robbins PF; Ilyas S; Prickett TD; Gartner JJ; Crystal JS; Roberts IM; Trebska-McGowan K; Wunderlich JR; Yang JC; Rosenberg SA
    Nat Med; 2016 Apr; 22(4):433-8. PubMed ID: 26901407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes.
    Gros A; Tran E; Parkhurst MR; Ilyas S; Pasetto A; Groh EM; Robbins PF; Yossef R; Garcia-Garijo A; Fajardo CA; Prickett TD; Jia L; Gartner JJ; Ray S; Ngo L; Wunderllich JR; Yang JC; Rosenberg SA
    J Clin Invest; 2019 Nov; 129(11):4992-5004. PubMed ID: 31609250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
    Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
    Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
    Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
    Gros A; Robbins PF; Yao X; Li YF; Turcotte S; Tran E; Wunderlich JR; Mixon A; Farid S; Dudley ME; Hanada K; Almeida JR; Darko S; Douek DC; Yang JC; Rosenberg SA
    J Clin Invest; 2014 May; 124(5):2246-59. PubMed ID: 24667641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient.
    Wieland A; Kamphorst AO; Adsay NV; Masor JJ; Sarmiento J; Nasti TH; Darko S; Douek DC; Xue Y; Curran WJ; Lawson DH; Ahmed R
    Cancer Immunol Immunother; 2018 Nov; 67(11):1767-1776. PubMed ID: 30167863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1
    Donia M; Kjeldsen JW; Andersen R; Westergaard MCW; Bianchi V; Legut M; Attaf M; Szomolay B; Ott S; Dolton G; Lyngaa R; Hadrup SR; Sewell AK; Svane IM
    Clin Cancer Res; 2017 Oct; 23(19):5779-5788. PubMed ID: 28679768
    [No Abstract]   [Full Text] [Related]  

  • 9. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.
    Bräunlein E; Lupoli G; Füchsl F; Abualrous ET; de Andrade Krätzig N; Gosmann D; Wietbrock L; Lange S; Engleitner T; Lan H; Audehm S; Effenberger M; Boxberg M; Steiger K; Chang Y; Yu K; Atay C; Bassermann F; Weichert W; Busch DH; Rad R; Freund C; Antes I; Krackhardt AM
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
    Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
    Front Immunol; 2018; 9():14. PubMed ID: 29403496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1.
    Poran A; Scherer J; Bushway ME; Besada R; Balogh KN; Wanamaker A; Williams RG; Prabhakara J; Ott PA; Hu-Lieskovan S; Khondker ZS; Gaynor RB; Rooney MS; Srinivasan L
    Cell Rep Med; 2020 Nov; 1(8):100141. PubMed ID: 33294862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An immunogenic personal neoantigen vaccine for patients with melanoma.
    Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
    Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
    Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood.
    Peng S; Zaretsky JM; Ng AHC; Chour W; Bethune MT; Choi J; Hsu A; Holman E; Ding X; Guo K; Kim J; Xu AM; Heath JE; Noh WJ; Zhou J; Su Y; Lu Y; McLaughlin J; Cheng D; Witte ON; Baltimore D; Ribas A; Heath JR
    Cell Rep; 2019 Sep; 28(10):2728-2738.e7. PubMed ID: 31484081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
    Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
    J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
    Strønen E; Toebes M; Kelderman S; van Buuren MM; Yang W; van Rooij N; Donia M; Böschen ML; Lund-Johansen F; Olweus J; Schumacher TN
    Science; 2016 Jun; 352(6291):1337-41. PubMed ID: 27198675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonality of CD4
    Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
    Front Immunol; 2019; 10():1336. PubMed ID: 31275310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell surface marker-based capture of neoantigen-reactive CD8
    Chatani PD; Lowery FJ; Parikh NB; Hitscherich KJ; Yossef R; Hill V; Gartner JJ; Paria B; Florentin M; Ray S; Bera A; Parkhust M; Robbins P; Krishna S; Rosenberg SA
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer.
    Sukegawa K; Shitaoka K; Hamana H; Kobayashi E; Miyahara Y; Fujii K; Tsuda K; Saeki S; Nagata T; Ozawa T; Saito S; Fujii T; Muraguchi A; Shiku H; Kishi H
    Eur J Immunol; 2020 Oct; 50(10):1580-1590. PubMed ID: 32441316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoantigen-targeted CD8
    Puig-Saus C; Sennino B; Peng S; Wang CL; Pan Z; Yuen B; Purandare B; An D; Quach BB; Nguyen D; Xia H; Jilani S; Shao K; McHugh C; Greer J; Peabody P; Nayak S; Hoover J; Said S; Jacoby K; Dalmas O; Foy SP; Conroy A; Yi MC; Shieh C; Lu W; Heeringa K; Ma Y; Chizari S; Pilling MJ; Ting M; Tunuguntla R; Sandoval S; Moot R; Hunter T; Zhao S; Saco JD; Perez-Garcilazo I; Medina E; Vega-Crespo A; Baselga-Carretero I; Abril-Rodriguez G; Cherry G; Wong DJ; Hundal J; Chmielowski B; Speiser DE; Bethune MT; Bao XR; Gros A; Griffith OL; Griffith M; Heath JR; Franzusoff A; Mandl SJ; Ribas A
    Nature; 2023 Mar; 615(7953):697-704. PubMed ID: 36890230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.